Evaluation Software Development GmbH   Report issue

For profit Phase 2
Founded: Innsbruck Austria (2018)
Status: No NME R&D (2018)

Organization Overview

First Clinical Trial
2019
NCT04124367
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Evaluation Software Development GmbH

Active Ingredients

Drugs in Phase 2 Trials (1)

porcine brain-derived peptide preparation (cerebrolysin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1